Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 207: Ebola Vaccines in Healthy Adults
NCT02231866Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2014
- Primary completion
- Apr 2017
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cAd3-EBO and cAd3-EBOV in Ebola virus disease (EVD) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Solicited systemic and local reactogenicity signs and symptoms at 7 days, Occurrence of adverse events of all severities at 4 weeks and 1 more. Started Aug 2014; status: completed.
02
Drugs
cAd3-EBOcAd3-EBOV
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02231866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231866.